The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The insulins available without a prescription come in vials and pens that may need ... teamed up with drugmaker Novo Nordisk to sell its own brand, called ReliOn insulin, which sells for as ...

Argentina Diabetes Devices Market To Reach US$ 1,031.89 Million By 2033, Growing At A CAGR Of 7.48% Astute Analytica ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

The global smart insulin pens market, currently estimated at US$ 3,927.3 million in 2023, is projected to exhibit robust ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

While the police have suggested that the case appears to be a suicide ... with cupboards and drawers searched. A pen drive was reported missing from the premises. In a conversation with CNN-News18, ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...